A B C D Figure E1 MR-proANP (pmol/L) CT-proAVP (pmol/L) CRP (mg/L)

Slides:

Advertisements

Similar presentations

Algebra Recap Solve the following equations (i) 3x + 7 = x (ii) 3x + 1 = 5x – 13 (iii) 3(5x – 2) = 4(3x + 6) (iv) 3(2x + 1) = 2x + 11 (v) 2(x + 2)

Advertisements

Pneumonia Why do we need to know about it? Long recognized as a major cause of death, Pneumonia has been studied intensively since late 1800s. Despite.

1 Financial Mathematics Clicker review session, Midterm 01.

1 Financial Mathematics Clicker review session, Final.

Financial Mathematics Clicker review session, Midterm 01 1.

1 Financial Mathematics Clicker review session, Midterm 01.

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Trends in incidence and mortality, England 1988 to 2008.

Diagnostic Criteria: Severe Community-Acquired Pneumonia Antonio Anzueto The University of Texas Health Science Center at San Antonio, Texas.

8.1.4 Can it still be factored? Factoring Completely I can factor out a common factor.

NS4301 Summer Term 2015 Predicting Expropriation.

 What are the signs to diagnose severe pneumonia?  Enumerate 4 organisms for community acquired pneumonia.

ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.

基督再來（一）. 經文： 1 你們心裡不要憂愁；你們信神，也當信我。 2 在我父的家裡有許多住處；若是沒有，我就早已告訴你們了。我去原是為你們預備地去。 3 我若去為你們預備了地方，就必再來接你們到我那裡去，我在那裡，叫你們也在那裡， ] ( 約 14 ： 1-3)

Preventing Sepsis in Wales

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Association of cardiac troponin, CK-MB, and postoperative.

Title of Abstract Goes Here – Please Make Sure Study Number is Listed in Title Author’s Names Author’s Affiliations Background: Patients with tumors Patients.

ΟΡΓΑΝΩΣΗ ΚΑΙ ΔΙΟΙΚΗΣΗ ΕΠΙΧΕΙΡΗΣΕΩΝ 3 Ο ΜΑΘΗΜΑ. ΟΙ ΜΕΓΑΛΕΣ ΕΠΙΧΕΙΡΗΣΕΙΣ Η δημιουργία μεγάλων επιχειρήσεων είναι ένα από τα χαρακτηριστικά του 20 ου αιώνα.

From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

Quetiapine Fumarate Quetiapine Fumarate is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar.

Figure 1. Rate of antimicrobial resistance in S. pneumoniae

Lung squamous cell carcinoma

Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy? Wayne C. Levy,

Distance and Midpoint In The Coordinate Plane

The Perfect Marriage! Ephesians 5:21-33.

Online Gifts Buy for wishes happy mother's day to yours choice and with happy gifts find here:

Thirty-day mortality of nosocomial systemic bacterial infections according to antibiotic susceptibility in an 800-bed teaching hospital in France D.

ФОНД ЗА РАЗВОЈ РЕПУБЛИКЕ СРБИЈЕ

بنــام خــدا.

قطاع المحروقات الموريتاني: الوضعية الحالية والآفاق

CAP Therapy Babak Sayad Associate Professor of Infectious Diseases

Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators

Evidence Behind the 4-Hour Rule for Initiation of Antibiotic Therapy in Community- Acquired Pneumonia Kenneth T. Yu, MD, MBA, Peter C. Wyer, MD Annals.

Слайд-дәріс Қарағанды мемлекеттік техникалық университеті

2481, , 2022, 2023, , , , , 2399, 2400,

.. -"""--..J '. / /I/I =---=-- -, _ --, _ = :;:.

KANSAS SB 123 Drug Possession Sentencing

وضعیت موجود مرگ و میر و علل مرگ غیر مادری در افراد سال کارشناس اداره سلامت میانسالان معصومه آرشین چی همدان 27 و 28 تیرماه 1396.

II //II // \ Others Q.

Пасиви и пасивни операции Активи и активни операции

Как да кандидатстваме по НИФ

ОПЕРАТИВНА ПРОГРАМА “ИНОВАЦИИ И КОНКУРЕНТОСПОСОБНОСТ“ „Подобряване на производствения капацитет в МСП“

'III \-\- I ', I ,, - -

I1I1 a 1·1,.,.,,I.,,I · I 1··n I J,-·

Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia F.M. Brunkhorst, B. Al-Nawas, F. Krummenauer,

The Impact of Prior Heart Failure Hospitalizations on Long-term Mortality Differs by Baseline Risk of Death Naga V.A. Kommuri, MD, Todd M. Koelling,

Index Notation Sunday, 24 February 2019.

Supplemental Figure 1A Pt Pt Pre-treatment

Solving Equations 3x+7 –7 13 –7 =.

Volume 67, Issue 6, Pages (June 2005)

Laura K. Certain, Jeffrey C. Way, Matthew J. Pezone, James J. Collins

Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration M. Cushman et al. Circulation. 2005;112:25-31.

Flow Diagram of the Trial Selection Process

Example Make x the subject of the formula

Supplemental Figure 6 Effect of p. o

The End Mark 13: John (Jack) W Rendel.

Comparative receiver operating characteristic (ROC) curves and the area under the curve (AUC) in association with 30-day mortality for severity scores.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

NS4301 Summer Term 2015 Economic Fundamentals

. '. '. I;.,, - - "!' - -·-·,Ii '.....,,......, -,

Volume 62, Issue 3, Pages (September 2002)

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Effects of GIP and GLP-1 infusion on MR-proANP levels.

Time course of levels of serum C-reactive protein (CRP; normal < 5 mg/l) and procalcitonin (PCT; normal < 0.1 ng/ml). Time course of levels of serum C-reactive.

Objective: Explain survivorship curves

U A B II III I IV 94.

Presentation transcript:

A B C D Figure E1 MR-proANP (pmol/L) CT-proAVP (pmol/L) CRP (mg/L) 10000 1000 p<0.0002 ns ns 1000 100 MR-proANP (pmol/L) 100 CT-proAVP (pmol/L) 10 10 1 1 0.1 typ. bacterial atypical viral mixed unknown typ. bacterial atypical viral mixed unknown C D typ. bacterial atypical viral mixed unknown 0.1 1 10 100 1000 p=0.0002 p=0.015 ns CRP (mg/L) typ. bacterial atypical viral mixed unknown 0.001 0.01 0.1 1 10 100 1000 p<0.0001 p=0.025 ns PCT (ng/mL) Figure E1

A B C D Figure E2 1 2 3 4 CRB-65 score MR-proANP (pmol/L) 1 2 3 4 1 2 3 4 10 100 1000 10000 p<0.0001 CRB-65 score MR-proANP (pmol/L) 1 2 3 4 0.1 10 100 1000 p<0.0001 CRB-65 score CT-proAVP (pmol/L) C D 1 2 3 4 0.001 0.01 0.1 10 100 1000 p<0.0001 CRB-65 score PCT (ng/mL) Figure E2

A B C D Figure E3 survival death survival death CRP (mg/L) survival 10000 1000 p<0.0001 p<0.0001 1000 100 MR-proANP (pmol/L) 100 CT-proAVP (pmol/L) 10 10 1 1 0.1 survival death survival death C D 1000 p=0.029 1000 p<0.0001 100 100 10 CRP (mg/L) 10 PCT (ng/mL) 1 0.1 1 0.01 0.1 0.001 survival death survival death Figure E3

A B C D Figure E4 ns no prior antibiotics prior antibiotics 0.1 1 10 100 1000 p<0.0001 CT-proAVP (pmol/L) 10000 p<0.0001 1000 100 MR-proANP (pmol/L) 10 1 no prior antibiotics prior antibiotics C D 1000 ns 1000 p<0.0001 100 100 10 CRP (mg/L) 10 PCT (ng/mL) 1 0.1 1 0.01 0.1 0.001 no prior antibiotics prior antibiotics no prior antibiotics prior antibiotics Figure E4

A B C D Figure E5 MR-proANP (pmol/L) CT-proAVP (pmol/L) 10000 1000 p<0.0001 p<0.0001 1000 100 MR-proANP (pmol/L) 100 CT-proAVP (pmol/L) 10 10 1 1 0.1 outpatient treatment inpatient treatment outpatient treatment inpatient treatment C D 1000 p<0.0001 1000 p<0.0001 100 100 10 CRP (mg/L) 10 PCT (ng/mL) 1 0.1 1 0.01 0.1 0.001 outpatient treatment inpatient treatment outpatient treatment inpatient treatment Figure E5

Figure E6 MR-proANP (pmol/L) CT-proAVP (pmol/L) 5000 500 500 50 50 5 5 PSI I PSI II PSI III PSI IV PSI V PSI I PSI II PSI III PSI IV PSI V Figure E6

inpatients: 28-days mortality Figure E7

CRB-65 class 2-4: 28-days mortality Figure E8